Clinical Trials
76 trialsNCT01366612 2026-04-03
FLUBUTBI
Hackensack Meridian Health
Phase 3 Terminated
NCT03926624 2026-01-22
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Delta-Fly Pharma, Inc.
Phase 3 Terminated
NCT04266301 2026-01-13
STIMULUS-MDS2
Novartis
Phase 3 Terminated
NCT04161885 2025-10-06
VIALE-T
AbbVie
Phase 3 Terminated
NCT05054543 2025-06-27
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
Apollomics Inc.
Phase 3 Terminated
NCT06108739 2025-06-03
ATG Plus Low-dose PT-Cy for GVHD Prevention
Peking University People's Hospital
Phase 3 Terminated
NCT03765541 2025-04-10
DEXAML-03
University Hospital, Toulouse
Phase 3 Terminated
NCT03016130 2025-04-07
UF-BMT-LDND-101
University of Florida
Phase 3 Terminated
NCT05079230 2025-04-04
ENHANCE-3
Gilead Sciences
Phase 3 Terminated
NCT03746054 2025-03-17
PALERMO
University Hospital, Angers
Phase 3 Terminated
NCT04778397 2025-02-05
ENHANCE-2
Gilead Sciences
Phase 3 Terminated
NCT02612311 2024-12-13
UNITY-CLL
TG Therapeutics, Inc.
Phase 3 Terminated
NCT03616470 2024-07-29
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
GlycoMimetics Incorporated
Phase 3 Terminated
NCT04571645 2024-04-15
AML
Jazz Pharmaceuticals
Phase 3 Terminated
NCT02013167 2024-03-05
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3 Terminated
NCT05020665 2024-01-10
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
Kronos Bio
Phase 3 Terminated
NCT05438498 2023-09-08
Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
MediMergent, LLC
Phase 3 Terminated
NCT04326764 2023-02-16
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Goethe University
Phase 3 Terminated
NCT03504410 2023-02-08
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
Cornerstone Pharmaceuticals
Phase 3 Terminated
NCT04095858 2023-02-08
CATHY
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01339910 2023-01-04
BMT CTN 0901
Medical College of Wisconsin
Phase 3 Terminated
NCT04093505 2022-07-01
GnG
University Hospital Heidelberg
Phase 3 Terminated
NCT02999854 2022-05-24
HATCY
Kiadis Pharma
Phase 3 Terminated
NCT02927938 2022-04-21
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
Wake Forest University Health Sciences
Phase 3 Terminated
NCT03151408 2022-03-10
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Helsinn Healthcare SA
Phase 3 Terminated
NCT02545283 2022-01-11
MIRROS
Hoffmann-La Roche
Phase 3 Terminated
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT01246752 2021-10-29
AML
University Hospital Carl Gustav Carus
Phase 3 Terminated
NCT00766779 2021-10-14
HCT Versus CT in Elderly AML
European Society for Blood and Marrow Transplantation
Phase 3 Terminated
NCT02298166 2021-10-06
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
University of Ulm
Phase 3 Terminated
NCT01439347 2021-09-09
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT00003056 2021-05-06
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
Takeda
Phase 3 Terminated
NCT01827930 2020-12-31
MIM
Institut Bergonié
Phase 3 Terminated
NCT01518959 2020-07-16
D-HEM
Semmelweis University
Phase 3 Terminated
NCT00513747 2020-04-22
Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT02115386 2019-12-10
MACS1532
Novartis
Phase 3 Terminated
NCT02174445 2019-12-02
DECLINE
University Hospital Freiburg
Phase 3 Terminated
NCT00568633 2019-09-24
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Stanford University
Phase 3 Terminated
NCT01539291 2019-08-20
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)
Gilead Sciences
Phase 3 Terminated
NCT01659021 2019-08-14
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 3 Terminated
NCT01039376 2019-07-30
PROLONG
Novartis
Phase 3 Terminated
NCT00748189 2019-06-25
COMPLEMENT 1
Novartis
Phase 3 Terminated
NCT03079505 2019-01-23
DANIN
Hamad Medical Corporation
Phase 3 Terminated
NCT02785900 2018-12-12
CASCADE
Seagen Inc.
Phase 3 Terminated
NCT01980875 2018-11-19
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 3 Terminated
NCT01980888 2018-11-19
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 3 Terminated
NCT01732913 2018-11-16
Yosemite
Gilead Sciences
Phase 3 Terminated
NCT01732926 2018-11-16
Bridalveil
Gilead Sciences
Phase 3 Terminated
NCT00004874 2018-01-17
Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
University of Nebraska
Phase 3 Terminated
NCT02108951 2017-10-27
ENESTswift
Novartis
Phase 3 Terminated